Emcure Pharmaceuticals Limited (EMCURE) Stock Price & Analysis

2 Followers

EMCURE Stock Chart & Stats

₹2,322.35₹86.50(3.87%)

At close: Nov 12 3:30 PM GMT+5:30

Day’s Range: INR 2,240.10 - INR 2,342.00
52-Week Range: INR 1,325.00 - INR 2,342.00
Previous Close: INR 2,235.85
Volume: N/A
Average Volume (3M): 36.71K
Market Cap: INR 424.16B
Enterprise Value: INR 385.01B
Total Cash (Recent Filing): INR 6.02B
Total Debt (Recent Filing): INR 16.59B
Price to Earnings (P/E): 40.1
Beta: 0.93
Next Earnings: Feb 11, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Sep 04, 2026
Dividend Yield: 0.16%

Bulls Say, Bears Say

Bulls Say

Strong Revenue And EPS Growth

Strong FY2026 revenue growth indicates expanding demand for Emcure’s pharmaceutical portfolio, while faster EPS growth shows operating leverage or improved profitability. If sustained, this combination can strengthen reinvestment capacity and support durable earnings growth over coming quarters.

Improving Profitability

Improved net income, a roughly 10% net margin, and mid-teens operating profitability indicate that growth is translating into meaningful earnings rather than relying solely on higher sales. Healthy operating profitability can support resilience and continued investment across therapies and markets.

Conservative Leverage And Better Returns

Low debt relative to equity gives Emcure financial flexibility as it scales, while high-teens ROE signals improved capital efficiency. This balance can support investment in pharmaceutical operations without placing excessive pressure on financing capacity or shareholder returns.

Bears Say

Weak Cash Conversion

Although cash generation remains positive, converting only about 58% of reported net income into free cash flow indicates a persistent gap between accounting earnings and available cash. Continued weakness could limit internally funded investment and reduce flexibility for capital allocation.

Gross Margin Volatility

Sharp year-over-year movement in reported gross margin makes underlying profitability harder to assess and reduces earnings comparability. If volatility persists, it may complicate planning, obscure the durability of operating gains, and make future margin performance less predictable.

Absolute Debt Increase

The rise in absolute debt creates a need for continued borrowing discipline even though leverage remains conservative today. As the business expands, further debt accumulation could increase financing obligations and gradually reduce flexibility if earnings or cash conversion weaken.

Emcure Pharmaceuticals Limited News

Emcure to Attend JM Financial Investor Conference in Mumbai

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals Limited operates in the pharmaceutical industry, although the release does not specify its primary products or

1w ago

Emcure Pharma Faces Rs 57.7 Crore Tax Penalty in Ongoing Litigation

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) just unveiled an announcement. Emcure Pharmaceuticals Limited has disclosed that it has received multiple orders from the Income-tax Department imposing aggregate penalties of Rs

1M ago

Emcure conducts 45th AGM via virtual platform, underscores regulatory compliance

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026, via video conferencing and other audio-visual

1M ago

Emcure Pharma Sets Virtual AGM for September, Publishes FY 2025-26 Annual Report

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has shared an update. Emcure Pharmaceuticals Limited has released its Annual Report for the financial year 2025-26 and announced that its 45th Annual General

2M ago

Emcure Plans Series of Investor Meets at Key Mumbai Conferences

An announcement from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) is now available. Emcure Pharmaceuticals Limited has announced a tentative schedule of participation in several major analyst and investor conferences in

3M ago

Emcure Pharma Maps Out Investor Conference Roadshow for August–September 2026

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has issued an update. Emcure Pharmaceuticals Limited has announced a series of scheduled analyst and investor meetings at prominent investor conferences in Mumbai and

3M ago

Emcure reshapes board as chairman retires and CEO takes helm

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has provided an update. Emcure Pharmaceuticals has announced a reshuffle in its board leadership, driven by the impending retirement of Chairman and Non-executive Director

3M ago

Emcure Pharma Files SEBI Dematerialisation Compliance Certificate

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has shared an announcement. Emcure Pharmaceuticals Limited has submitted a confirmation certificate to Indian stock exchanges for the quarter ended June 30, 2026, as

4M ago

Emcure Pharmaceuticals Reports Brief Fire-Linked Shutdown at Pune Plant

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals has reported a fire incident at the utility block of its Plant I manufacturing facility in

9M ago

Emcure Pharmaceuticals Confirms SEBI Dematerialisation Compliance for December Quarter

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) just unveiled an update. Emcure Pharmaceuticals has informed the stock exchanges that it has received a confirmation certificate from its Registrar and Share Transfer

10M ago

EMCURE FAQ

What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?

Emcure Pharmaceuticals Limited lowest stock price was ₹1325.00 and its highest was ₹2342.00 in the past 12 months.

What is Emcure Pharmaceuticals Limited’s market cap?

Emcure Pharmaceuticals Limited’s market cap is ₹424.16B.

When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Emcure Pharmaceuticals Limited’s earnings last quarter?

Emcure Pharmaceuticals Limited released its earnings results on Nov 03, 2026. The company reported ₹17.2 earnings per share for the quarter, beating the consensus estimate of ₹14.9 by ₹2.3.

Is Emcure Pharmaceuticals Limited overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Emcure Pharmaceuticals Limited pay dividends?

Emcure Pharmaceuticals Limited pays a dividend of ₹3.6 which represents an annual dividend yield of 0.16%. See more information on Emcure Pharmaceuticals Limited dividends here

What is Emcure Pharmaceuticals Limited’s EPS estimate?

Emcure Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Emcure Pharmaceuticals Limited have?

Emcure Pharmaceuticals Limited has 189,710,650 shares outstanding.

What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?

Emcure Pharmaceuticals Limited reported an EPS of ₹17.2 in its last earnings report, beating expectations of ₹14.9. Following the earnings report the stock price went up 5.315%.

Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:EMCURE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description